Work

364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer

Year: 2010

Type: conference-abstract

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(10)72071-1

Authors: T. Shimizu, A.W. Tolcher, P. LoRusso, K. Papadopoulos, A. Patnaik, L. Smith, M. Keegan

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1968441562

Cites:

Cited by: 6

Related to: 10